Treat to target in gout
Open Access
- 1 January 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (suppl_1), i20-i26
- https://doi.org/10.1093/rheumatology/kex442
Abstract
The treat-to-target (T2T) approach has been successfully implemented in a number of diseases. T2T has been proposed for rheumatic diseases such as RA, spondyloarthritis, lupus, and recently for gout. The level of evidence for such approaches differs from one condition to the other (moderate to high for hyperlipidaemia, for example). Practice is based on the best available evidence at any time, and in absence of good evidence for T2T in gout, some suggest a conservative only-treat-symptoms approach. Evidence suggests that not treating gout to target in the long term is overall associated with worsening outcomes, such as flares, tophi and structural damage, which is associated to loss of quality of life and mortality. Different targets have been proposed for hyperuricaemia in gout; lower than 6 mg/dl (0.36 mmol/l) for all patients, at least < 5 mg/dl (0.30 mmol/l) for patients with severe-polyarticular or tophaceous-gout.This publication has 47 references indexed in Scilit:
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyHealth and Quality of Life Outcomes, 2012
- Gout: why is this curable disease so seldom cured?Annals Of The Rheumatic Diseases, 2012
- Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver DiseasesJournal of Hepatology, 2011
- Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic goutRheumatology, 2010
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals Of The Rheumatic Diseases, 2010
- GoutThe Lancet, 2010
- British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of GoutRheumatology, 2007
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals Of The Rheumatic Diseases, 2006